【摘要】 纤溶酶原激活物抑制剂-1(plasminogen activator inhibitor 1,PAI-1)作为体内组织型纤溶酶原激活物(tissue-type plasminogen activator,t-PA)和尿激酶型纤溶酶原激活物(urokinase-type plasminogen activator,u-PA)的主要抑制剂,与动静脉血栓、出血和凝血异常、细胞迁移密切相关,进而引起缺血性脑卒中、冠心病、静脉血栓、肿瘤转移、出血、股骨头坏死、流产等一系列疾病的发生发展。同时,体内血浆PAI-1活性水平又受血脂、血糖等调节,进一步参与肥胖、糖尿病、高脂血症等疾病的进程,又影响着上述相关疾病的预后。更多还原

【Abstract】 Plasminogen activator inhibitor 1(PAI-1), as the main inhibitor of tissue-type plasminogen activator(t-PA) and urokinase-type plasminogen activator(u-PA) in body, is closely related to arteriovenous thrombosis, abnormal coagulation and cell migration, which further leads to the occurrence and development of a series of diseases including ischemic stroke, coronary heart disease, venous thrombosis, tumor metastasis, hemorrhage, femoral head necrosis and abortion. Meanwhile, the level of plasma PAI-1 in the body is regulated by blood lipids and blood glucose, which further involves obesity, diabetes, hyperlipidemia and other diseases, and affects the prognosis of the above-mentioned related diseases. PAI-1 research covers a wide range of areas.更多还原